Clinical Trial Update: A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury [Phase 2]

View source ↗

Summary

Oragenics is conducting a Phase 2a pilot, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and pharmacodyna…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Concussion
• Traumatic Brain Injury

Drugs mentioned

• ONP-002

Snippet

Sponsor: Oragenics, Inc. | Conditions: Mild Traumatic Brain Injury, Concussion | Phase 2 | Status: NOT_YET_RECRUITING